ARMP:Armata Pharmaceuticals Inc Snapshot | Charting | News | Options
$2.17 NYSE MKT LLC 7:00a ET
May 19 '25 		Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously ... PR Newswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
     PR Newswire

    All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met

    AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy

    Full Story →

    Headline News
    Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
    4:05p ET May 14 '25 PR Newswire
    Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
    7:00a ET May 1 '25 PR Newswire
    More News →
    Day  11.9%Week  8.50%Month  9.60%More Charting →
    July 3 '25. Markets Closed.
    Last $2.17
    Day change   11.86%$0.23
    Open $1.98
    Gap at open $0.04
    Previous close $1.94
    Trading volume 43,768
    10 Day avg vol. 20,860
    Shares out. 36.2Mil
    Market cap. $78.5Mil
    Trading activity Above Avg.
    Previous data from yesterday, July 2 '25.

    Historical Price Performance
    3 month   73.60% 
    6 month   4.83% 
    1 year   18.73% 
    2 year   92.04% 

    Earnings
    Previous 12m -$0.11
    Next 12m Estimate -$1.94
    P/E ratio --
    Revenue 5Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2025 All rights reserved.